Bristol/ImClone's Erbitux Wholesale List Price Will Be $2,400 Per Dose
This article was originally published in The Pink Sheet Daily
Executive Summary
The colorectal cancer therapy will be available to patients Feb. 25. Bristol will use its Oncology Therapeutic Network subsidiary as Erbitux' single-source distributor.
You may also be interested in...
Erbitux Gets C-Code Reimbursement; Waits For Green Light On J-Code
ImClone has not seen "obstacles" to reimbursement across all patients. During the quarter, Erbitux generated $17.5 mil. in sales.
Erbitux Gets C-Code Reimbursement; Waits For Green Light On J-Code
ImClone has not seen "obstacles" to reimbursement across all patients. During the quarter, Erbitux generated $17.5 mil. in sales.
Bristol/ImClone's Erbitux Clears FDA; Undergoing Two Confirmatory Trials
Erbitux is indicated for treatment of EGFR-expressing, metastatic colorectal carcinoma in combination with irinotecan or as monotherapy. Launch is expected within two weeks using product manufactured at Lonza Biologics facility.